GILEAD SCIENCES, INC. (GILD) Stock Profile — Insider Trades & Financials

Revenue$7.9B

Net Income$2.2B

EPS$6.78

Market Cap$172.3B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Daniel O'Day

CEO & Executive Director

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.

Employees: 10,000
Headquarters: FOSTER CITY, CA, United States
Website: www.gilead.com

Peer ComparisonRevenue ($B)

▾

⚡

Core Efficiency

ROE?

9.62%

ROA?

3.70%

Op. Margin?

25.03%

📊

Profitability Ratios

Net Margin?

27.55%

Current Ratio?

1.55

Loading company sections...

GILEAD SCIENCES, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness